Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC)

被引：0
|
作者：
Santini, V. [1 ]
Silverman, L. [2 ]
Seymour, J. [3 ]
Fenaux, P. [4 ]
Mufti, G. [5 ]
Hellstrom-Lindberg, E. [6 ]
Sanz, G.
Finelli, C.
Backstom, J.
McKenzie, D.
Beach, C.
机构：
[1] Aou Careggi Univ Florence, UF Ematol, Florence, Italy
[2] Mt Sinai Sch Med, New York, NY USA
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Univ Paris 13, Hop Avicenne, F-93430 Villetaneuse, France
[5] Kings Coll London, London, England
[6] Karolinska Univ Hosp, Stockholm, Sweden
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70208-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S133 / S133
页数：1
相关论文
共 50 条
  • [1] Rates of infection and bleeding are not increased in patients with myelodysplastic syndromes (MDS) treated with azacitidine compared with supportive care.
    Silverman, LR
    McKenzie, DR
    Peterson, BL
    Odchimar-Reissig, R
    Hinkle, R
    Backstrom, JT
    Larson, RA
    BLOOD, 2005, 106 (11) : 709A - 709A
  • [2] Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA)
    Santini, Valeria
    Fenaux, Pierre
    Mufti, Ghularn J.
    Hellstrom-Lindberg, Eva
    Silverman, Lewis B.
    List, Alan
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 583 - 584
  • [3] AVALIDATION OF A POST-HYPOMETHYLATING AGENT FAILURE (HMAF) PROGNOSTIC MODEL IN MDS PATIENTS TREATED WITH RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC)
    Nazha, A.
    Sekeres, M.
    Komrokji, R.
    Steensma, D.
    Kantarjian, H.
    Roboz, G.
    Fenaux, P.
    Prebet, T.
    Azarnia, N.
    Zbyszewski, P.
    Fruchtman, S.
    Santini, V.
    Silverman, L.
    Platzbecker, U.
    Garcia-Manero, G.
    LEUKEMIA RESEARCH, 2017, 55 : S147 - S148
  • [4] Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS
    Gore, S.
    Fenaux, P.
    Santini, V.
    Bennett, J. M.
    Silverman, L. R.
    Seymour, J. F.
    Hellstrom-Lindberg, E.
    Swern, A. S.
    Beach, C. L.
    List, A. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (PTS) with advanced malignant pleural mesothelioma (MPM)
    Jassem, Jacek
    Ramlau, Rodryg
    Santoro, Armando
    Schuette, Wolfgang
    Chemaissani, Assad
    Hong, Shengyan
    Blatter, Johannes
    Adachi, Susumu
    Hanauske, Axel-R
    Manegold, Christian
    ANNALS OF ONCOLOGY, 2006, 17 : 214 - 214
  • [6] Azacitidine (AZA) versus best supportive care (BSC) before non-myeloablative allogeneic stem cell transplantation (RIC Allo-SCT) for myelodysplastic syndromes (MDS): a study by the SFGM-TC
    Damaj, G.
    Duhamel, A.
    Robin, M.
    Milpied, N.
    Michallet, M.
    Chevallier, P.
    Beguin, Y.
    Nguyen, S.
    Lioure, B.
    Blaise, D.
    Mallaird, N.
    Rubio, M.
    Fegueux, N.
    Cornillon, J.
    Francois, S.
    Mohty, M.
    Hyun, A.
    Bulabois, C.
    Garnier, F.
    Fenaux, P.
    Agha, I. Yakoub
    BONE MARROW TRANSPLANTATION, 2013, 48 : S150 - S150
  • [7] Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)
    Santini, V.
    Fenaux, P.
    Mufti, G. J.
    Hellstroem-Lindberg, E.
    List, A. F.
    Silverman, L. R.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Itzykson, Raphael
    Thepot, Sylvain
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    BLOOD, 2010, 116 (21) : 199 - 199
  • [9] Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma
    Jassem, Jacek
    Ramlau, Rodryg
    Santoro, Armando
    Schuette, Wolfgang
    Chemaissani, Assad
    Hong, Shengyan
    Blatter, Johannes
    Adachi, Susumu
    Hanauske, Axel
    Manegold, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1698 - 1704
  • [10] COST-EFFECTIVENESS ANALYSIS OF A DIGITAL HEALTH APPLICATION (DIGA) PLUS BEST SUPPORTIVE CARE (BSC) COMPARED TO BSC IN GERMAN EPISODIC MIGRAINE PATIENTS
    Walter, E.
    Wegner, S.
    Burziwoda, D.
    VALUE IN HEALTH, 2022, 25 (12) : S129 - S129
12345